Kristin Brooks04.22.21
Nanoform Finland Plc, a nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, have partnered to explore synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms. This collaboration aims to provide the pharmaceutical industry with new capabilities in patient centric therapies.
The product innovation target is to combine Nanoform’s fast dissolution nanoformed particles with Aprecia’s ZipDose technology platform for rapid disintegration to enable high performance buccal and oral delivery of medicines to patients where rapid absorption is essential. Additional benefits may include lower dosage products, less excipient content, and reduced pill burden.
“Small is Powerful – and now in ZipDose! At the heart of everything we do is the patient. This is a fantastic opportunity to demonstrate the power of small for rapid drug absorption, potentially bypassing the first-pass metabolism via a novel dosage form such as buccal delivery with Aprecia’s 3DP technology platforms. We look forward to this exciting collaboration and to supporting our pharmaceutical partners with this unique offering for fast acting and quick dissolving nanomedicines,” said Prof. Edward Hæggström, CEO of Nanoform.
“Aprecia’s proprietary 3DP technology platforms, are focused on providing solutions to our partner’s toughest formulation challenges that can’t be achieved through conventional manufacturing technologies. The opportunity to join forces with Nanoform will enable new fast acting and high performance buccal and oral dosage forms not previously seen in the industry. With the first and only FDA approval for a product utilizing these leading edge 3DP technology platforms, along with the world’s only commercial scale equipment and manufacturing process, Aprecia is paving the way for our current partners and future customers to make the medication experience better for both the patient and the caregiver,” said Chris Gilmore, CEO of Aprecia.
The product innovation target is to combine Nanoform’s fast dissolution nanoformed particles with Aprecia’s ZipDose technology platform for rapid disintegration to enable high performance buccal and oral delivery of medicines to patients where rapid absorption is essential. Additional benefits may include lower dosage products, less excipient content, and reduced pill burden.
“Small is Powerful – and now in ZipDose! At the heart of everything we do is the patient. This is a fantastic opportunity to demonstrate the power of small for rapid drug absorption, potentially bypassing the first-pass metabolism via a novel dosage form such as buccal delivery with Aprecia’s 3DP technology platforms. We look forward to this exciting collaboration and to supporting our pharmaceutical partners with this unique offering for fast acting and quick dissolving nanomedicines,” said Prof. Edward Hæggström, CEO of Nanoform.
“Aprecia’s proprietary 3DP technology platforms, are focused on providing solutions to our partner’s toughest formulation challenges that can’t be achieved through conventional manufacturing technologies. The opportunity to join forces with Nanoform will enable new fast acting and high performance buccal and oral dosage forms not previously seen in the industry. With the first and only FDA approval for a product utilizing these leading edge 3DP technology platforms, along with the world’s only commercial scale equipment and manufacturing process, Aprecia is paving the way for our current partners and future customers to make the medication experience better for both the patient and the caregiver,” said Chris Gilmore, CEO of Aprecia.
